대사체학 시약 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Metabolomics Reagent Market

The future of the global metabolomics reagent market looks promising with opportunities in the pharmaceutical & biotechnology company, academic & research institute, and contract research organization markets. The global metabolomics reagent market is expected to reach an estimated $116 billion by 2035 from $43 billion in 2027 with a CAGR of 14.5% from 2027 to 2035. The major drivers for this market are the increasing adoption of personalized medicine, the rising demand for advanced diagnostic tools, and the growing investment in research and development.

• Lucintel forecasts that, within the product type category, kits is expected to witness the highest growth over the forecast period due to increased use of metabolomic workflow kit bundles by life sciences organizations.
• Within the end use category, pharmaceutical & biotechnology companies will remain the largest segment over the forecast period due to rising research to identify biomarkers and develop pharmaceuticals.
• In terms of regions, North America will remain the largest region over the forecast period due to location of pharmaceutical and biotechnology research and development organizations.

Emerging Trends in Metabolomics Reagent Market

The market for metabolomics reagents is transitioning from a market focused on basic research to a market focused on research and development and other related applications from 2025 to 2027. Lucintel expects that the number of end-users in various industries will increase in the coming years. The market is still in an immature stage, and availability, reproducibility and reliability of data will determine the success of service providers.

• Sustainability: Metabolomics service providers are reducing solvent use in their activities; in 2025, a few service providers changed their focus to environmental sustainability. Reducing the ecological footprint of the supply chain is expected to be an important factor in the assessment of service providers by research organizations.
• Automation: Pharmaceutical companies are focusing on automation of metabolomics activities; integrating autonomous liquid handling with sample preparation is expected to change the industry in the coming years.
• Standardization: The Metabolomics Standards Initiative is creating and disseminating recommendations on metabolomics research in order to standardize the field. Collaboration across different research areas will also benefit from standardization.
• Multiplexed Workflows: The commercial landscape for LC-MS assays is evolving to include targeted-panels covering hundreds of analytes. Meanwhile untargeted analysis is also gaining traction. Moving forward, greater reagent usage is expected, as labs shift from performing single, one-off experiments to ongoing, continuous monitoring.
• Diversification of Supplier Bases: In the post Covid-19 market, customers are also re-evaluating alternate sources for enzymes, isotopes, and other research chemicals. In 2025, many procurement professionals still preferred to adopt a strategy of dual sourcing. New supplier facilities, located in more markets, are expected, as are changes to supplier's employment and business strategies, to include more localized production and contract manufacturing.

The most successful companies will be able to integrate both higher assay reliability and lower workflow costs. Companies which supply reagents that facilitate workflow integration will have a competitive edge. Green chemistry will help differentiate products, but performance will be the main factor driving customer choice. The best long term opportunities will exist in the in vitro diagnostic space.

Recent Developments in the Metabolomics Reagent Market

Metabolomics reagents market is progressing from exploratory research to well-defined, high-throughput analyses. Lucintel analysis of Metabolomics reagents market indicates that, during the period 2025-2027, increasing research in biopharmaceutical industry, and the rise of automation in mass spectrometry would be the major driving forces. The market would have strong competition among suppliers to develop and offer validated panels to instrument vendors and consumable reagents.

• Assay Panel Expansions: In January 2025, Thermo Fisher Scientific reported $42 billion revenue for the year 2024. With increasing revenues, Thermo Fisher is expected to sponsor research for development of new panels. These panels would boost the use of metabolomics in clinical, pharmaceutical and other research laboratories.
• Clinical Metabolomics: In February 2025, the U.S Food and Drug Administration permitted the first in vitro blood test for Alzheimer's disease. Thousands of metabolomics research have been conducted to identify various biomarkers for Alzheimer's and other neurological disorders. This regulatory approval has created a demand for metabolomics reagents, calibrators and quality controls.
• Automation Collaborations: In March 2025, Hamilton announced collaborations with various automation companies for sample preparation. Automation will create a higher demand of reagents and kits for sample preparation, and lower demand of standard reagents for research.
• Biopharma Adoption: The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) reported in April 2025, on the increasing use of biomarkers in the drug-discovery process. As biopharmaceutical companies (biopharma) tend to outsource the production of stable isotope standards and relied upon extraction reagents, it is imperative that sponsor companies ensure standards are being consistently measured and evaluated across different stages of a drug's lifecycle.
• Data Standardization: In May 2025, the Metabolomics Standards Initiative, continued its efforts to establish a standard for the adequate reporting of information pertaining to the identity of metabolites, as well as the experimental data. As standards are developed, sponsor companies will tend to purchase traceable standards, and reagents from suppliers that develop and validate extraction methodologies. As such, the demand for undifferentiated reagents will be negatively impacted.

The development of a standard will further strengthen the position of stable isotope reagents in the marketplace, especially in conjunction with automated liquid chromatography-mass spectrometry (LC-MS) instrumentation. Clinical and regulatory demand will more than offset the variability in research funding. Expect M&A activity among reagents and chemicals distributors.

Strategic Growth Opportunities in the Metabolomics Reagent Market

The market for metabolomics reagents is expected to grow in the next few years as a result of increased requirements for reproducible workflows in the clinical research and precision nutrition markets, as well as in the bioprocessing and food testing markets. From 2024 to 2026, continued cost reductions in analysis and higher data requirements will increase the number of metabolomics markets. According to Lucintel, there will be five primary markets.

• Clinical Diagnosis: Reagents for metabolomics can be used to develop tests for various cancers and other metabolic disorders. In January 2025, the FDA approved 12 companion diagnostics based on mass spectrometry. During the next 3 to 5 years, the clinical validation of these tests will lead to replacement of exploratory kits with reagent systems.
• Biopharmaceutical Industry: Reagents of metabolomics can be used to monitor cell culture and other process steps of pharmaceutical manufacturing. In March 2025, it was estimated that there were more than 20,000 biopharmaceutical projects.
• Food and Beverage Industry: Metabolomics can be used for authentications of food origin and to test for food fraud. In February 2025, the European Commission reported that member states of the EU conducted more than 1,500 food checks to verify compliance with food fraud legislation.
• Sustainable Reagent Formats: Certain formats (i.e. .concentrated reagents), reagents in which the solvent has been reduced, and reagents with extended shelf-lives can decrease laboratory waste and reduce the volume of waste generated during transportation. These formats may also provide a competitive edge in the marketplace. The European Union (EU) REACH directive was updated in April 2025 to include additional substances. As a result, procurement departments within the EU may prefer reagents (and other chemicals) in these formats, which may result in charging a higher price for these reagents.
• New Markets: More localized production and a greater presence of technical personnel may lead to the expansion of metabolomics in other regions (i.e. Latin America, the Middle East, and parts of Asia). India has a burgeoning biotech industry. In May 2025, it was estimated that the Indian biotech industry was worth $165 billion.

It is expected that, within the next five years, the suppliers of metabolomics reagents that expand their business to include reagent standardization, applications-based chemistry and on-site reagent production, will experience growth and gain market share. It is expected that there will be increased demand for reagents used for biomedical research, bioprocess control and food integrity and authenticity. It is expected that the suppliers of these reagents would benefit from long-term business relationships with research laboratories.

Metabolomics Reagent Market Drivers and Challenges

As the global economy recovers and advances in biomedical science and technology transform the regulatory landscape, the metabolomics reagents market is expected to expand. Favorable reagent demands are expected from the clinical, pharmaceutical, and other diagnostic and testing industries. As per Lucintel, the market is expected to gain from market inclusions and automation. Continuant reagent price cuts, inconsistent standards and supply, and market regulations are expected to constrain and restrict the market.

The factors responsible for driving this market include :

• Growing Demand for Precision Medicine: The recent focus on individualized and personalized medicine and research in the field of rare diseases and cancers has increased the need for advanced metabolomics. The National Institutes of Health (NIH), U.S, and other government organizations have been funding and encouraging translational researches in the field of metabolomics. Precision medicine programs are anticipated to stimulate the demand for metabolomics reagents.
• Improved Analysis Technologies: Innovations in mass spectrometry, NMR, and chromatography, together with advances in automation and artificial intelligence, have dramatically reduced the time required to perform metabolomics experiments. During the study period, high-resolution mass spectrometers became more widely available and enabled metabolomics research to be conducted with a throughput that was limited only by the length of the chromatographic run. This technology, in conjunction with advances in automation and reagents, facilitated studies that previously had not been feasible due to large sampling requirements.
• Booming Metabolomics in Pharmaceuticals: In 2025, the world's pharmaceutical research and development (R&D) efforts focused on approximately 20,000 clinical trials, providing sustained market growth. It is expected that the next few years will see further growth as pharmaceutical companies outsource early-stage research and development, especially in the area of drug and diagnostics development. Increased research in the field will stimulate further growth in the market for metabolomics-related consumables.
• Rising Metabolomics in Food and Agriculture: Metabolomics reagents are relevant to food and crop research, quality, safety, and authenticity. In 2025, the mandate by food safety agencies to better control food safety and quality increased the demand for validated testing. It is expected that in the next few years, producers and regulators will be required to use reagents to test food safety and quality and to demonstrate compliance with legal standards.
• High Laboratory Automation: Recent trends in laboratory automation and ready-to-use kits have resulted in a significant increase in the number of samples that a laboratory worker can process in a given time. In June 2025, several academic and pharmaceutical laboratories fully automated sample processing, and each laboratory processed several hundred biological samples in a day. Due to the increased automation and rapid throughput, there is increased demand for pre-fabricated automation consumables. Automation will change the reagent market in the next 3-5 years, and the effect will be increasing the volume of tests, reducing the manual errors in a laboratory.

The challenges facing this market include:

High Cost of Reagents and Testing: Some of the reagents used in metabolomics are very expensive, and small and medium laboratories in developing countries find it very difficult to acquire these reagents. In addition to the high cost of reagents and supplies, in July 2025, a few metabolomics labs had to implement advanced untargeted methods to answer specific research questions. These methods were very costly and increased the overall cost of metabolomics studies. In the next 3 to 5 years, metabolomics kit suppliers will have to reduce the cost of kits to improve the overall affordability of the kits. Suppliers will also have to provide reagents with improved analytical performance.

• Standardization and Reproducibility Gaps: Variability in methods for sample preparation, purity of reagents, configuration of instruments, and reporting practices results in differences in analyses conducted in different laboratories. International metabolomics initiatives have focused on establishing uniform criteria and processes for quality and data control. This is expected to aid in meeting customer expectations for validated and traceable reagents. Suppliers that offer certified reference materials, detailed and validated procedures, and reagents with consistent quality are expected to experience growth. The acceptance of products lacking standardization and validation is expected to decline in regulated markets.
• Supply Chain and Regulatory Environment: Several of the reagents used in metabolomics are comprised of raw materials and biologics that require cold-chain transportation. In addition, a high degree of international trade results in reliance on supply from different regions. A high degree of regulation of trade and transportation as well as varying controls on the movement of hazardous materials pose a challenge to the supply of chemicals used by laboratories. In 2025, these issues continued to impact the supply of reagents and equipment.
• Supply-chain and Regulatory Complexity: The raw materials and ingredients used in the production of metabolomics reagents are often dispersed and require transport in cold-chain conditions. In addition, the implementation of strict regulations on the movement of chemicals across borders further complicates the supply of these reagents. Laboratory suppliers continued to suffer the effects of unfavorable supply and demand conditions, especially regarding transportation and changing regulations, in November 2025.

In the next 5 to 10 years, it is expected that there will be greater unpredictability in the supply of raw materials. This will lead to long lead times, increased inventory costs, and greater risk that a product will not be available and will need to be substituted. The best way for companies to proactively combat these issues will be to locate manufacturing facilities in multiple regions, improve their demand forecasting, and create adequate regulatory documentation. This would enable companies to ensure that the products they manufacture and sell would be available to customers that have strict requirements concerning the availability of products they purchase.

The increasing adoption of metabolomics in fields such as medical research and agriculture will maintain positive growth for the metabolomics reagents market. The market is nevertheless constrained by a number of factors. Most notably, high prices for metabolomics reagents coupled with lack of standardization negatively affect ease of use and adoption. It is expected that companies will be able to address the standardization concerns by integrating more robust and systematic supply chains to improve the overall efficiency of the market.

List of Metabolomics Reagent Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies metabolomics reagent market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the metabolomics reagent market companies profiled in this report include-

• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Bruker Corporation
• Waters Corporation
• Bio-Rad Laboratories, Inc.

Metabolomics Reagent Market by Segment

The study includes a forecast for the global metabolomics reagent market by product type, application, end use, and region.

Metabolomics Reagent Market by Product Type [Value ($B) from 2019 to 2035]:

• Kits
• Assays
• Reagents
• Others

Metabolomics Reagent Market by Application [Value ($B) from 2019 to 2035]:

• Biomarker Discovery
• Drug Discovery
• Toxicology Testing
• Nutrigenomics
• Others

Metabolomics Reagent Market by End Use [Value ($B) from 2019 to 2035]:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
• Others

Metabolomics Reagent Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Metabolomics Reagent Market

Market insights indicate the metabolomics reagents market will flourish in the 2025-2027 timeframe with continued advancements in areas such as precision medicine and biopharmaceuticals. Furthermore, the continued adoption of high resolution mass spectrometry will foster market growth. Current trends show competing companies are acquiring and partnering with firms that will augment their overall offerings.

• United States: According to Lucintel's most recent report, the recently announced $2 billion Thermo Fisher Scientific's (US) investment to expand their bioprocess and other analytical services in the US further enhances their manufacturing capacity, and when coupled with continued funding by the National Institute of Health (NIH) for metabolomics, should enhance the availability of validated reagents to academic and pharmaceutical markets in the next 5 years.
• China: BGI is releasing new mass spectrometry and multi-omics services. Other providers in the industry are following suit. The direction of the policy is to create more local supply chains and evaluate more biomedical reagents. Consequently, hospitals and research institutes are more likely to accept and adopt locally sourced biomedical reagents. (March 2025)
• Germany: The investment in R&D of analytical tools by German pharmaceutical companies, coupled with Bruker's focus on timsMetabo and higher-order proteomics, will consolidate German's leadership in the metabolomics space. Bruker expects 2024 revenue in excess of €3 billion. (February 2025)
• India: The metabolomics space is expected to grow thanks to the $2.48 billion allotted in the 2025 Indian Budget to private-public partnerships. (February 2025)
• Japan: High-resolution mass spectrometry is becoming the norm in the pharmaceutical and clinical industries, and Shimadzu is positioned to capture this growing market. The 2025 Japan science and technology budget was ¥5 trillion. (April 2025)

Features of the Global Metabolomics Reagent Market

• Market Size Estimates: metabolomics reagent market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: metabolomics reagent market size by product type, application, end use, and region in terms of value ($B).
• Regional Analysis: metabolomics reagent market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different product types, applications, end uses, and regions for the metabolomics reagent market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the metabolomics reagent market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the metabolomics reagent market by product type (kits, assays, reagents, and others), application (biomarker discovery, drug discovery, toxicology testing, nutrigenomics, and others), end use (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Metabolomics Reagent Market by Product Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product Type
• 4.3 Kits : Trends and Forecast 2019 to 2035
• 4.4 Assays : Trends and Forecast 2019 to 2035
• 4.5 Reagents : Trends and Forecast 2019 to 2035
• 4.6 Others : Trends and Forecast 2019 to 2035

5. Global Metabolomics Reagent Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Biomarker Discovery : Trends and Forecast 2019 to 2035
• 5.4 Drug Discovery : Trends and Forecast 2019 to 2035
• 5.5 Toxicology Testing : Trends and Forecast 2019 to 2035
• 5.6 Nutrigenomics : Trends and Forecast 2019 to 2035
• 5.7 Others : Trends and Forecast 2019 to 2035

6. Global Metabolomics Reagent Market by End Use

• 6.1 Overview
• 6.2 Attractiveness Analysis by End Use
• 6.3 Pharmaceutical & Biotechnology Companies : Trends and Forecast 2019 to 2035
• 6.4 Academic & Research Institutes : Trends and Forecast 2019 to 2035
• 6.5 Contract Research Organizations : Trends and Forecast 2019 to 2035
• 6.6 Others : Trends and Forecast 2019 to 2035

7. Regional Analysis

• 7.1 Overview
• 7.2 Global Metabolomics Reagent Market by Region

8. North American Metabolomics Reagent Market

• 8.1 Overview
• 8.2 North American Metabolomics Reagent Market by Product Type
• 8.3 North American Metabolomics Reagent Market by End Use
• 8.4 The United States Metabolomics Reagent Market
• 8.5 Canadian Metabolomics Reagent Market
• 8.6 Mexican Metabolomics Reagent Market

9. European Metabolomics Reagent Market

• 9.1 Overview
• 9.2 European Metabolomics Reagent Market by Product Type
• 9.3 European Metabolomics Reagent Market by End Use
• 9.4 German Metabolomics Reagent Market
• 9.5 French Metabolomics Reagent Market
• 9.6 Italian Metabolomics Reagent Market
• 9.7 Spanish Metabolomics Reagent Market
• 9.8 The United Kingdom Metabolomics Reagent Market

10. APAC Metabolomics Reagent Market

• 10.1 Overview
• 10.2 APAC Metabolomics Reagent Market by Product Type
• 10.3 APAC Metabolomics Reagent Market by End Use
• 10.4 Chinese Metabolomics Reagent Market
• 10.5 Indian Metabolomics Reagent Market
• 10.6 Japanese Metabolomics Reagent Market
• 10.7 South Korean Metabolomics Reagent Market
• 10.8 Indonesian Metabolomics Reagent Market

11. ROW Metabolomics Reagent Market

• 11.1 Overview
• 11.2 ROW Metabolomics Reagent Market by Product Type
• 11.3 ROW Metabolomics Reagent Market by End Use
• 11.4 Middle Eastern Metabolomics Reagent Market
• 11.5 South American Metabolomics Reagent Market
• 11.6 African Metabolomics Reagent Market

12. Competitor Analysis

• 12.1 Product Portfolio Analysis
• 12.2 Operational Integration
• 12.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

• 13.1 Value Chain Analysis
• 13.2 Growth Opportunity Analysis
  • 13.2.1 Growth Opportunity by Product Type
  • 13.2.2 Growth Opportunity by Application
  • 13.2.3 Growth Opportunity by End Use
• 13.3 Emerging Trends in the Global Metabolomics Reagent Market
• 13.4 Strategic Analysis
  • 13.4.1 New Product Development
  • 13.4.2 Certification and Licensing
  • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

• 14.1 Competitive Analysis Overview
• 14.2 Agilent Technologies, Inc.
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.3 Thermo Fisher Scientific Inc.
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.4 Bruker Corporation
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.5 Waters Corporation
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.6 Bio-Rad Laboratories, Inc.
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.7 Danaher Corporation
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.8 Shimadzu Corporation
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.9 PerkinElmer, Inc.
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.10 Merck KGaA
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.11 LECO Corporation
  • Company Overview
  • Metabolomics Reagent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

15. Appendix

• 15.1 List of Figures
• 15.2 List of Tables
• 15.3 Research Methodology
• 15.4 Disclaimer
• 15.5 Copyright
• 15.6 Abbreviations and Technical Units
• 15.7 About Us
• 15.8 Contact Us